0102030405
Fidaxomicin CAS 873857-62-6 Pharmaceutical Raw Material
02
introduce
introduce
Fidaxomicin is a potent, narrow-spectrum 18-membered macrolide antibiotic and key pharmaceutical API. It specifically targets Gram-positive bacteria by inhibiting bacterial RNA polymerase, approved for treating Clostridium difficile-associated diarrhea (CDAD).
Our products adhere to strict international quality standards, ensuring high purity, stable performance, and reliable supply for pharmaceutical formulation and biomedical research.
02
Physical and chemical properties
Fidaxomicin exhibits critical physical and chemical characteristics supporting its pharmaceutical and research applications, as follows:
- Density: 1.3±0.1 g/cm³
- Melting Point: 161 °C
- Boiling Point: 1046.4±65.0 °C at 760 mmHg
- Solubility: Soluble in Slightly heated Chloroform, heated DMSO, and Methanol; insoluble in water
- Density: 1.3±0.1 g/cm³
- Melting Point: 161 °C
- Boiling Point: 1046.4±65.0 °C at 760 mmHg
- Solubility: Soluble in Slightly heated Chloroform, heated DMSO, and Methanol; insoluble in water
1. Precise Antibacterial Spectrum and Gut Microbiota-Friendly
As a narrow-spectrum antibiotic, it has excellent antibacterial activity against Gram-positive bacteria (especially Clostridium difficile) but little effect on Gram-negative bacteria. Compared with broad-spectrum antibiotics such as vancomycin, it is barely absorbed and mainly exerts its effect in the gastrointestinal tract, without excessively disrupting the balance of normal intestinal flora, thus reducing the risk of subsequent problems caused by flora disturbance.
2. Unique Mechanism of Action and Lower Recurrence Rate
It exerts antibacterial effects by inhibiting the transcription initiation process of bacterial RNA polymerase, with a special target site (binding to the DNA template-RNA polymerase complex to prevent initial DNA strand separation). Different from the mechanism of traditional macrolide antibiotics, it is not prone to cross-resistance. At the same time, it can inhibit the sporulation of Clostridium difficile. Compared with conventional therapeutic drugs, it can better maintain clinical efficacy and reduce the recurrence rate of Clostridium difficile infection.
As a narrow-spectrum antibiotic, it has excellent antibacterial activity against Gram-positive bacteria (especially Clostridium difficile) but little effect on Gram-negative bacteria. Compared with broad-spectrum antibiotics such as vancomycin, it is barely absorbed and mainly exerts its effect in the gastrointestinal tract, without excessively disrupting the balance of normal intestinal flora, thus reducing the risk of subsequent problems caused by flora disturbance.
2. Unique Mechanism of Action and Lower Recurrence Rate
It exerts antibacterial effects by inhibiting the transcription initiation process of bacterial RNA polymerase, with a special target site (binding to the DNA template-RNA polymerase complex to prevent initial DNA strand separation). Different from the mechanism of traditional macrolide antibiotics, it is not prone to cross-resistance. At the same time, it can inhibit the sporulation of Clostridium difficile. Compared with conventional therapeutic drugs, it can better maintain clinical efficacy and reduce the recurrence rate of Clostridium difficile infection.
1. Core Indication: Mainly used for the treatment of Clostridium difficile infection (CDI), including Clostridium difficile-associated diarrhea, and is a specific antibacterial drug for this condition.
2. Other Antibacterial Applications: It has antibacterial activity against Gram-positive bacteria such as staphylococci, most anaerobic Gram-positive bacilli and cocci, and can be used for the treatment of related infections caused by these susceptible bacteria.
3. Research Application Value: Due to its specific inhibition of bacterial transcription process, it can be used as a tool drug in biological research related to bacterial transcription mechanism.
2. Other Antibacterial Applications: It has antibacterial activity against Gram-positive bacteria such as staphylococci, most anaerobic Gram-positive bacilli and cocci, and can be used for the treatment of related infections caused by these susceptible bacteria.
3. Research Application Value: Due to its specific inhibition of bacterial transcription process, it can be used as a tool drug in biological research related to bacterial transcription mechanism.
We implement strict full-process quality control, with each batch of Fidaxomicin undergoing rigorous testing of key indicators including purity, solubility, stability, antibacterial activity, and metabolite profile to meet standards.
Equipped with a stable raw material supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including formulation optimization, application guidance, and post-sales technical support to address customer-specific needs.
Equipped with a stable raw material supply chain, we ensure continuous large-scale supply. Our professional technical team provides tailored services, including formulation optimization, application guidance, and post-sales technical support to address customer-specific needs.
As a first-in-class narrow-spectrum macrolide antibiotic, Fidaxomicin revolutionizes the treatment of Clostridium difficile-associated diarrhea by targeting pathogens while preserving intestinal flora. With its unique mechanism of action, low resistance risk, exceptional product quality, and reliable supply capacity, we are committed to providing high-quality Fidaxomicin API and professional services for global pharmaceutical companies, research institutions, and clinical applications.
Choose our Fidaxomicin to meet your needs in pharmaceutical formulation, antibacterial research, and clinical treatment. Contact us for more product details and cooperation support.
Choose our Fidaxomicin to meet your needs in pharmaceutical formulation, antibacterial research, and clinical treatment. Contact us for more product details and cooperation support.